Type 2 Drugs: EU Approves “Victoza,” FDA Extends Review of “Onglyza”

The FDA had originally intended to complete its review by April 30. Although a majority of the agency’s Endocrinologic and Metabolic Drugs Advisory Committee believes that saxagliptin does not present an “unacceptable” risk of creating cardiovascular problems in normal type 2 users, they want additional time to study the drug’s effects among type 2 patients who are already at a higher risk of cardiovascular problems.

May 6, 2009

The European Union's drug regulation agency has recommended that the EU approve the marketing of "Victoza" (liraglutide), a type 2 drug developed by Novo Nordisk.

The recommendation by the European Medicines Agency, based in London, could mean that the drug will reach the European market by late July.

At the same time, the U.S. Food and Drug Administration has announced that it wants 90 more days to review Onglyza (saxagliptin), a type 2 diabetes drug developed by AstraZeneca PLC and Bristol-Meyers Squibb Co.

The FDA had originally intended to complete its review by April 30. Although a majority of the agency's Endocrinologic and Metabolic Drugs Advisory Committee believes that saxagliptin does not present an "unacceptable" risk of creating cardiovascular problems in normal type 2 users, they want additional time to study the drug's effects among type 2 patients who are already at a higher risk of cardiovascular problems.

Liraglutide is in the same class as Byetta (exenatide), a long-acting glucagon-like peptide-1 analog. Like Byetta, the drug reduces blood glucose levels by increasing insulin secretion, slowing gastric emptying, and suppressing mealtime secretion of glucagon. secretion. It is intended to be taken as a once-daily drug.

Saxagliptin is a dipeptidyl peptidase-4 inhibitor, an oral glucose-lowering drug that works much the same as exenatide.  

Click Here To View Or Post Comments

Categories: Blood Glucose, Byetta, Diabetes, Diabetes, Food, Heart Care & Heart Disease, Insulin, Medications Research, Novo Nordisk, Onglyza, Type 2 Issues, Type 2 Medications, Victoza


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (2)

You May Also Be Interested In...


Comments

Posted by Anonymous on 25 October 2009

can i take victoza if i am already on insulin please help

Posted by Anonymous on 5 November 2009

Can Victoza help if I have overweight?


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.